Stryker Co. (NYSE:SYK) Shares Sold by Grandfield & Dodd LLC

Grandfield & Dodd LLC trimmed its stake in Stryker Co. (NYSE:SYK) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,520 shares of the medical technology company’s stock after selling 521 shares during the quarter. Stryker makes up 2.1% of Grandfield & Dodd LLC’s portfolio, making the stock its 16th biggest holding. Grandfield & Dodd LLC’s holdings in Stryker were worth $30,102,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in SYK. Freedom Wealth Alliance LLC acquired a new position in shares of Stryker in the fourth quarter worth $26,000. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 61 shares during the last quarter. Quarry LP acquired a new position in Stryker in the first quarter valued at $27,000. HBC Financial Services PLLC acquired a new position in Stryker in the fourth quarter valued at $37,000. Finally, Bourgeon Capital Management LLC acquired a new position in Stryker in the fourth quarter valued at $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.6 %

Shares of NYSE:SYK traded down $2.02 during trading on Friday, hitting $325.43. The company’s stock had a trading volume of 1,884,151 shares, compared to its average volume of 959,865. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The stock’s 50-day moving average price is $350.01 and its two-hundred day moving average price is $312.50. The company has a market capitalization of $123.82 billion, a PE ratio of 39.45, a PEG ratio of 2.64 and a beta of 0.89.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The company’s revenue was up 11.8% compared to the same quarter last year. As a group, sell-side analysts expect that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is 38.79%.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Citigroup upped their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada upped their target price on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and upped their target price for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research note on Wednesday, January 31st. Finally, Wells Fargo & Company boosted their price target on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $340.45.

Insider Buying and Selling

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.